134 related articles for article (PubMed ID: 37310466)
1. Efficacy and safety of EGFR inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report.
Krishna A; Sathya M; Mukesh S; Athiyamaan MS; Banerjee S; Sunny J; Srinivas C; Lobo D; Makkapatti BS; Jawahar V
Med Oncol; 2023 Jun; 40(7):203. PubMed ID: 37310466
[TBL] [Abstract][Full Text] [Related]
2. Role of gefitinib in patients with recurrent or metastatic cervical carcinoma ineligible or refractory to systemic chemotherapy: first study from Asia.
Sharma DN; Rath GK; Julka PK; Gandhi AK; Jagadesan P; Kumar S
Int J Gynecol Cancer; 2013 May; 23(4):705-9. PubMed ID: 23466569
[TBL] [Abstract][Full Text] [Related]
3. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Shi Y; Chen G; Wang X; Liu Y; Wu L; Hao Y; Liu C; Zhu S; Zhang X; Li Y; Liu J; Cao L; Cheng Y; Zhao H; Zhang S; Zang A; Cui J; Feng J; Yang N; Liu F; Jiang Y; Gu C;
Lancet Respir Med; 2022 Nov; 10(11):1019-1028. PubMed ID: 35662408
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
5. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
Goncalves A; Fabbro M; Lhommé C; Gladieff L; Extra JM; Floquet A; Chaigneau L; Carrasco AT; Viens P
Gynecol Oncol; 2008 Jan; 108(1):42-6. PubMed ID: 17980406
[TBL] [Abstract][Full Text] [Related]
7. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
Zampino MG; Magni E; Massacesi C; Zaniboni A; Martignetti A; Zorzino L; Lorizzo K; Santoro L; Boselli S; de Braud F
Cancer; 2007 Aug; 110(4):752-8. PubMed ID: 17594712
[TBL] [Abstract][Full Text] [Related]
8. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
9. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
10. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
11. Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.
Xu Y; Zheng Y; Sun X; Yu X; Gu J; Wu W; Zhang G; Hu J; Sun W; Mao W
Oncotarget; 2015 Nov; 6(35):38429-39. PubMed ID: 26392415
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.
Hotta K; Saeki S; Yamaguchi M; Harada D; Bessho A; Tanaka K; Inoue K; Gemba K; Shiojiri M; Kato Y; Ninomiya T; Kubo T; Kishimoto J; Shioyama Y; Katsui K; Sasaki J; Kiura K; Sugio K
ESMO Open; 2021 Aug; 6(4):100191. PubMed ID: 34153652
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study.
Hou X; Li M; Wu G; Feng W; Su J; Jiang H; Jiang G; Chen J; Zhang B; You Z; Liu Q; Chen L
JAMA Netw Open; 2023 Feb; 6(2):e2255050. PubMed ID: 36753281
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial.
Fu Z; Yang X; Wang W; Deng L; Zhang T; Bi N; Wang X; Chen D; Zhou Z; Wang L; Liang J
Radiat Oncol; 2020 Jun; 15(1):155. PubMed ID: 32563259
[TBL] [Abstract][Full Text] [Related]
16. Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive
Jiang X; Li X; Tu L; Cai J; Wei M; Wu Z; Sun L
J Int Med Res; 2020 Oct; 48(10):300060520955030. PubMed ID: 33032475
[TBL] [Abstract][Full Text] [Related]
17. The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study.
Yu J; Xu Z; Li A; Zhang J; Wang Y; Zhao H; Zhu H
Drug Des Devel Ther; 2019; 13():3419-3424. PubMed ID: 31576114
[TBL] [Abstract][Full Text] [Related]
18. Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial.
Lim SW; Park S; Kim Y; Cho JH; Park SE; Lee H; Kim HK; Kim SM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2018 Oct; 124():293-297. PubMed ID: 30268476
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
